Evidence map›Paper›PMID 41201487›Full record

ArticleInternational journal of clinical pharmacy2026

Nephrotoxicity of polymyxin B and colistin sulfate in patients with multidrug-resistant gram-negative bacteria infections: a parametric time-to-event analysis.

Yuanfang Qin, Qin Ding, Shuqi Huang, Ruwei Yang, Shengnan Zhang, Tingting Wu, Jingjing Liu, Qi Pei

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of clinical pharmacy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yuanfang Qin *Department of Pharmacy, The Third Xiangya Hospital, Central South University, No.138, Tongzipo Road, Changsha, 410013, China.
Qin Ding *Department of Pharmacy, The Third Xiangya Hospital, Central South University, No.138, Tongzipo Road, Changsha, 410013, China.
Shuqi HuangDepartment of Pharmacy, The Third Xiangya Hospital, Central South University, No.138, Tongzipo Road, Changsha, 410013, China.
Ruwei YangDepartment of Pharmacy, The Third Xiangya Hospital, Central South University, No.138, Tongzipo Road, Changsha, 410013, China.
Shengnan ZhangDepartment of Pharmacy, The Third Xiangya Hospital, Central South University, No.138, Tongzipo Road, Changsha, 410013, China.
Tingting WuDepartment of Pharmacy, The Third Xiangya Hospital, Central South University, No.138, Tongzipo Road, Changsha, 410013, China.
Jingjing LiuDepartment of Critical Care Medicine, The Third Xiangya Hospital, Central South University, No.138, Tongzipo Road, Changsha, 410013, China. ivljingjing@126.com.
Qi PeiDepartment of Pharmacy, The Third Xiangya Hospital, Central South University, No.138, Tongzipo Road, Changsha, 410013, China. peiqi1028@126.com.

Funding

National Natural Science Foundation of China,China ， 8237131654
6 · The paper itself

Abstract

introductionMultidrug-resistant Gram-negative bacteria (MDR-GNB), especially carbapenem-resistant strains, pose a major therapeutic challenge in intensive care units and are associated with high morbidity and mortality. Polymyxin B (PMB) and colistin sulfate (CS) are the last-line agents for MDR-GNB infections; however, their clinical use is limited by nephrotoxicity. Although the steady-state 24-h area under the curve (AUC

aimThis study aimed to identify clinical and pharmacological factors influencing PMB- and CS-associated nephrotoxicity in critically ill patients with MDR-GNB infections and to establish AUC

methodWe retrospectively analyzed real-world data from 562 patients with MDR-GNB infections treated with PMB (n = 354) or CS (n = 208) at Xiangya Third Hospital, Central South University, between July 2018 and July 2023. Pharmacokinetic profiles were simulated using published models, and drug exposure parameters (AUC

resultsOverall, 39.4% of patients developed AKI, with a significantly higher incidence in the PMB group than in the CS group (51.7% vs. 18.4%). The final PMB model identified AUC

conclusionIn critically ill patients with MDR-GNB infections, higher plasma exposure to PMB and CS was strongly associated with increased nephrotoxicity. Exposure thresholds of AUC

Indexed as

Acute Kidney InjuryAnti-Bacterial AgentsColistinDrug Resistance, Multiple, BacterialGram-Negative Bacterial InfectionsPolymyxin BAdultAgedFemaleGram-Negative BacteriaHumansMaleMiddle AgedRetrospective StudiesAnti-Bacterial AgentsColistinPolymyxin BAcute kidney injuryColistin sulfateMultidrug-resistant gram-negative bacteriaParametric time-to-event analysisPolymyxin BSurvival analysis

Identifiers

PMID41201487

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.